2017
MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial
Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial. Journal Of Thoracic Oncology 2017, 12: s394-s395. DOI: 10.1016/j.jtho.2016.11.447.Peer-Reviewed Original ResearchAdvanced lung adenocarcinomaNivolumab therapyLung adenocarcinomaPreliminary dataAdenocarcinomaTherapyTrials
2016
Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.
Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. Journal Of Clinical Oncology 2016, 34: tps9102-tps9102. DOI: 10.1200/jco.2016.34.15_suppl.tps9102.Peer-Reviewed Original ResearchPD-1 therapyAdvanced lung adenocarcinomaLung adenocarcinomaResponse rateNivolumabAdenocarcinomaTherapyTrials